收费全文 | 2591102篇 |
免费 | 234652篇 |
国内免费 | 14043篇 |
耳鼻咽喉 | 35506篇 |
儿科学 | 80851篇 |
妇产科学 | 65812篇 |
基础医学 | 436813篇 |
口腔科学 | 68930篇 |
临床医学 | 230642篇 |
内科学 | 437067篇 |
皮肤病学 | 76339篇 |
神经病学 | 228768篇 |
特种医学 | 101828篇 |
外国民族医学 | 29篇 |
外科学 | 409647篇 |
综合类 | 86650篇 |
现状与发展 | 23篇 |
一般理论 | 2018篇 |
预防医学 | 222965篇 |
眼科学 | 58431篇 |
药学 | 174718篇 |
22篇 | |
中国医学 | 8507篇 |
肿瘤学 | 114231篇 |
2022年 | 22533篇 |
2021年 | 54192篇 |
2020年 | 34587篇 |
2019年 | 57449篇 |
2018年 | 68841篇 |
2017年 | 52306篇 |
2016年 | 57603篇 |
2015年 | 72504篇 |
2014年 | 106506篇 |
2013年 | 171317篇 |
2012年 | 68220篇 |
2011年 | 64348篇 |
2010年 | 109631篇 |
2009年 | 116098篇 |
2008年 | 51841篇 |
2007年 | 51559篇 |
2006年 | 63768篇 |
2005年 | 59290篇 |
2004年 | 61771篇 |
2003年 | 53214篇 |
2002年 | 43308篇 |
2001年 | 58400篇 |
2000年 | 49603篇 |
1999年 | 58828篇 |
1998年 | 60895篇 |
1997年 | 59830篇 |
1996年 | 56979篇 |
1995年 | 52570篇 |
1994年 | 46751篇 |
1993年 | 43867篇 |
1992年 | 37849篇 |
1991年 | 35496篇 |
1990年 | 32759篇 |
1989年 | 33276篇 |
1988年 | 31233篇 |
1987年 | 30415篇 |
1986年 | 28949篇 |
1985年 | 30321篇 |
1984年 | 32466篇 |
1983年 | 31186篇 |
1982年 | 36227篇 |
1981年 | 34613篇 |
1980年 | 32709篇 |
1979年 | 24664篇 |
1978年 | 25357篇 |
1977年 | 24311篇 |
1976年 | 21984篇 |
1975年 | 19806篇 |
1974年 | 18498篇 |
1973年 | 17809篇 |
Methods: Day 3 to day 7 after admission to a stroke unit, 64 persons with stroke were assessed twice, using the SwePASS, by two physiotherapists. Inter-rater reliability was determined using percentage-agreement and the rank-invariant method: relative position, relative concentration, and relative rank variance.
Results: The raters showed a percentage agreement of ≥75% in the assessments using the SwePASS. For 9 of the 12 items, the percentage agreement was >80%. For 8 of the 12 items, there was a statistically significant change in position, revealed in relative position values between 0.08 and 0.15. Three items had statistically significant positive relative concentration values between ?0.11 and 0.10. Except for a statistically significant negligible relative variance value of 0.01 for the items 1 and 8, there was no relative variance.
Conclusions: The SwePASS shows an acceptable inter-rater reliability, albeit with potential for improvement. The reliability can be improved by a consensus how to interpret the scale between the raters prior to implementation in the clinic. 相似文献
Background
Clear cell renal cell carcinoma (ccRCC) is known to occur across the adult lifetime traversing the spectrum of age-related organismal changes. Little is known as to how the aging process may affect the course of renal cell carcinoma (RCC) and the repertoire of genes involved.Methods
Using The Cancer Genome Atlas (n?=?436) and Cancer Genomics of the Kidney (n?=?89) datasets, we applied regression analysis to examine associations between patient age and gene expression profiles in ccRCC tumors and normal kidney tissues. Pathway enrichment analysis was performed to identify cellular process that is affected by aging in ccRCC. Moreover, connectivity mapping analysis was used to predict age-dependent response to drug treatments.Results
Our analysis revealed different age-dependent gene expression spectra in ccRCC and normal kidney tissues. These findings were significant and independently reproducible in both datasets examined. Age up-regulated genes, showing higher expression in older patients, were significantly enriched (false discovery rate <0.05) in normal tissues for pathways associated with immune response and extracellular matrix organization, whereas age up-regulated genes in tumors were enriched for metabolism and oxidation pathways. Strikingly, age down-regulated genes in normal cells were also enriched for metabolism and oxidation, while those in tumors were enriched for extracellular matrix organization. Further in silico analysis of potential drug targets predicted preferential efficacy of Phosphoinositide 3-kinase inhibitor or immunotherapy in association with age.Conclusion
We report on previously unrecognized associations between age and molecular underpinnings of RCC, including age-associated expression of genes implicated in RCC development or treatment. 相似文献Areas covered: the principal pharmacogenetic and non-genetic differences in the pharmacology of tamoxifen and endoxifen are evaluated. To this end, references from PubMed, Embase or Web of Science, among others, were reviewed As non-genetic factors, important differences and similarities such age, or adherence to tamoxifen therapy are comprehensively illustrated. Additionally, since CYP2D6 genotypes are considered the main limitation of tamoxifen, many studies have investigated the association between the worsened clinical outcomes in patients with non-functional CYP2D6 genotypes. In this review, an overview of the research on this field is presented. Also, a summary describing the literature about individualizing tamoxifen therapy with endoxifen concentrations and its limitations is listed.
Expert opinion: z-endoxifen hydrochloride is only investigated in the metastatic setting, still more research is required before its place in therapeutics is known. Similarly, monitoring tamoxifen efficacy based on endoxifen concentrations might not be overall recommended due to the limited evidence available. 相似文献